Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
AstraZeneca
Medtronic
McKesson
McKinsey

Last Updated: August 15, 2022

Investigational Drug Information for Tamibarotene


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Tamibarotene?

Tamibarotene is an investigational drug.

There have been 11 clinical trials for Tamibarotene. The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2021.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Promyelocytic, Acute. The leading clinical trial sponsors are Syros Pharmaceuticals, CytRx, and Japan Agency for Medical Research and Development.

There are four hundred and twenty-five US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Tamibarotene
TitleSponsorPhase
SY-1425 Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AMLSyros PharmaceuticalsPhase 2
Investigator-initiated Clinical Trial of MIKE-1Japan Agency for Medical Research and DevelopmentPhase 1/Phase 2
Investigator-initiated Clinical Trial of MIKE-1Nagoya UniversityPhase 1/Phase 2

See all Tamibarotene clinical trials

Clinical Trial Summary for Tamibarotene

Top disease conditions for Tamibarotene
Top clinical trial sponsors for Tamibarotene

See all Tamibarotene clinical trials

US Patents for Tamibarotene

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tamibarotene See Plans and Pricing Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP) See Plans and Pricing
Tamibarotene See Plans and Pricing Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
Tamibarotene See Plans and Pricing .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) See Plans and Pricing
Tamibarotene See Plans and Pricing Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
Tamibarotene See Plans and Pricing Aryl-cyanoguanidine compounds Bayer Pharma Aktiengesellschaft (Berlin, DE) See Plans and Pricing
Tamibarotene See Plans and Pricing Heteroaryl compounds as IRAK inhibitors and uses thereof Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tamibarotene

Drugname Country Document Number Estimated Expiration Related US Patent
Tamibarotene Australia AU2015272560 2034-06-09 See Plans and Pricing
Tamibarotene Canada CA2951627 2034-06-09 See Plans and Pricing
Tamibarotene Denmark DK3153508 2034-06-09 See Plans and Pricing
Tamibarotene European Patent Office EP3153508 2034-06-09 See Plans and Pricing
Tamibarotene Spain ES2792851 2034-06-09 See Plans and Pricing
Tamibarotene Japan JP2019206529 2034-06-09 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
AstraZeneca
Medtronic
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.